AI Article Synopsis
- Salivary ductal carcinoma is a rare and aggressive cancer with few effective treatment options, particularly for patients with HER2 amplification.
- A case study shows a patient achieved significant improvement in disease status after receiving a combination treatment of trastuzumab, lapatinib, and bevacizumab for over two years, despite prior therapies failing.
- The results suggest this combination therapy could serve as a promising non-cytotoxic treatment for HER2-overexpressing salivary gland tumors, especially for those unresponsive to single-agent trastuzumab.
Article Abstract
Background: Salivary ductal carcinoma is a rare cancer with poor prognosis and limited treatment options. Human epidermal receptor 2 (HER2)-directed treatment has been attempted in HER2-amplified or overexpressed salivary gland malignancies with limited success.
Methods: We report resolution of measurable disease and minimal residual disease in a patient with salivary duct cancer treated with trastuzumab, lapatinib, and bevacizumab, with treatment ongoing for more than 2 years.
Results: This treatment has been tolerated well except for grade 2 diarrhea and mucositis, which required a dose reduction of lapatinib to 1000 mg daily. The response observed was achieved in spite of receiving extensive prior therapy, including trastuzumab and/or chemotherapy for 20 months on which his tumors progressed.
Conclusion: The combination of trastuzumab, lapatinib, and bevacizumab may warrant investigation as a non-cytotoxic alternative for treatment of HER2-amplified or overexpressed salivary duct carcinoma and other HER2-amplified or overexpressed salivary gland tumors, particularly those not responsive to trastuzumab monotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893310 | PMC |
| http://dx.doi.org/10.1002/hed.23429 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tracheal mucosal keratosis: Case discussion and literature review.
Chron Respir Dis
January 2025
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
A 57-year-old female presented with a chief complaint of cough, with productive yellow sputum particularly severe in the morning. Bronchoscopy revealed inflammatory changes in both main bronchi, with abundant white purulent secretions and necrotic material adhering to the luminal surface. Histopathological examination showed chronic inflammatory changes in the mucosal tissue, with mild hyperplasia of the local squamous epithelium and evidence of keratinization in the surrounding area, consistent with a diagnosis of tracheal mucosal keratosis.
View Article and Find Full Text PDFQuantitative expression of estrogen, progesterone and human epidermal growth factor receptor-2 and their correlation with immunohistochemistry in breast cancer at Uganda Cancer Institute.
PLoS One
January 2025
Department of Clinical Support Services, Division of Laboratory and Pathology Medicine, Uganda Cancer Institute, Kampala, Uganda.
The detection of Estrogen Receptor (ER), Progesterone Receptor (PR), and Human epidermal growth factor receptor 2 (HER-2) is important for the stratification of breast cancer and the selection of therapeutic modalities. This study aimed to determine the quantitative expression of ER, PR and HER-2 using Immunohistochemistry and their correlation with quantitative baseline Ct values measured using Quantitative Polymerase Chain Reaction (PCR). This study also assessed the use of fresh breast tissue biopsies preserved in RNAlater solution in the quantitative detection of these receptors using PCR technique.
View Article and Find Full Text PDFSynthesis and Evaluation of a Bifunctional Chelator for Thorium-227 Targeted Radiotherapy.
J Med Chem
January 2025
Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States.
Thorium-227 (Th) is an α-emitting radionuclide currently under investigation for targeted alpha therapy. Available chelators used for this isotope suffer from challenging multistep syntheses. Here, we present the synthesis and preclinical evaluation of a novel bifunctional chelator, SCN-Bn-DOTHOPO, which contains an isothiocyanate group that is suitable for conjugation to biological molecules.
View Article and Find Full Text PDFExploring Benzo[d]thiazol-2-Amine Derivatives, Synthesis, and Molecular Docking Insights Potential Anticancer Agents Targeting HER Enzyme and DNA.
Appl Biochem Biotechnol
January 2025
Department of Chemistry, College of Science, University of Diyala, Baquba, Diyala, Iraq.
The synthesis and characterization of benzo[d]thiazol-2-amine derivatives, which were prepared by reacting benzothiazole with para-aminobenzophenone in ethanol, supplemented with glacial acetic acid. Subsequently, compound (2) was synthesized from compound (1) using NaNO, HPO, and HNO in a water-based solvent, resulting in 2-hydroxy-1-naphthaldehyde. Another derivative, compound (3), was synthesized by reacting compound (1) with vanillin under similar conditions.
View Article and Find Full Text PDFRadiolabeled HER2-targeted molecular probes in breast cancer imaging: current knowledge and future prospective.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Obstetrics and Gynecology Department, Tehran University of Medical Sciences, Tehran, Iran.
Breast cancer is the most frequent non-dermatologic malignancy in women. Breast cancer is characterized by the expression of the human epidermal growth factor receptor type 2 (HER2), and the presence or lack of estrogen receptor (ER) and progesterone receptor (PR) expression. HER2 overexpression is reported in about 20 to 25% of breast cancer patients, which is usually linked to cancer progression, metastases, and poor survival.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!